Managing itchy, dry, and inflamed skin can be challenging. Current treatments for eczema don’t work for everyone and may cause unwanted side effects or become less effective over time. That’s why we’re researching another potential option.
These clinical trials will help us learn if a potential new type of biologic called a trispecific is safe and if it can improve moderate to severe eczema when used with approved topical medicines
Most treatments today focus on only 1 or 2 parts of the immune system linked to inflammation and itching in eczema. The study medicine is designed to target 3 at the same time, which may help to better control symptoms.
By taking part in our Tilrek-AD Clinical Trials, you can help advance research aimed at improving the lives of people living with eczema.
Who may participate
Participation by people of all backgrounds is critical to advancing treatment options for eczema. The greater the representation among clinical trial participants, the more we learn about the study medicine and how it works for different people. Including people from all backgrounds helps us develop potential treatments that are more likely to be effective for everyone.
Condition
Moderate to severe eczema (atopic dermatitis or AD)
Age
12+ years
Medical history
Have been diagnosed with moderate to severe eczema for at least 12 months and topical medicines have not worked well
This information is a summary of the eligibility criteria across the studies in this program. Each study will have its own unique requirements for who may participate (eligibility criteria). To learn more about the requirements for a study that is actively recruiting, visit the study’s webpage below. Only the research study staff can determine if you qualify to enroll in the study.
Get started — See if you may be eligible
Answer a 15-minute questionnaire.
A first step as you consider these studies is to answer a 15-minute online questionnaire about your health and medical history. If your answers show these studies might be a good fit for you, you may choose to be referred to a study clinic that you select.
Speak with a study representative.
If you’re interested, you will then be asked to provide your contact information for a study representative to contact you and discuss the next steps.
Confirm your eligibility.
Your answers to these questions will only be linked to you if your responses indicate that you may be eligible to participate in this study and you choose to share your contact information with the study team. Pfizer study team members and our partners will have access to reports containing aggregated data that will not be directly linked back to you. Only the study staff can determine if you meet the study's eligibility criteria and are able to enroll.
Tilrek-AD Clinical Trials
Researching a study medicine compared to an approved medicine and a placebo in people 12 years and older with moderate to severe eczema.
Researching a study medicine compared to a placebo for people 12 years and older living with moderate to severe eczema.
About the study medicine
The study medicine is a type of biologic (made from living cells) called a trispecific, thought to work by blocking 3 different targets that cause the immune system to create unnecessary inflammation underneath your skin.
Most eczema treatments today focus on only 1 or 2 parts of the immune system linked to inflammation and itching.
By targeting 3 parts, we want to learn if the study medicine reduces the itchiness and discomfort associated with eczema and leads to clearer skin and greater control.
Frequently asked questions
Each clinical trial is unique and has different requirements to determine who is eligible to participate. You can learn more about the eligibility criteria on each clinical trial’s webpage. The study team will help you decide if taking part in one of our Tilrek-AD Clinical Trials is right for you.
- You will receive care from a team of dedicated specialists
- You will gain access to the latest research and may help advance the future of eczema treatments
- All clinical trial-related care and the study medicine will be provided at no cost
All clinical trials have possible risks. The known risks of taking part in these clinical trials will be explained to you during an informed consent process. This happens before you decide whether to participate.
A lot of information on the study medicine has been collected during previous clinical trials. By participating in one of these clinical trials, you will be helping researchers gather more information to better understand how well the study medicine may work in moderate to severe eczema. Researchers will also gain a greater understanding of the side effects that may occur.
You may have noticed that different people use different names for this skin condition. Some people call it "neurodermatitis," some refer to it as "atopic dermatitis," and some say "AD," but most people just call it "eczema."
All study-related medical care, the approved medicine, and the study medicine will be provided at no cost. You may also be reimbursed for any reasonable expenses you may have as a result of taking part in a clinical trial, such as parking and travel-related expenses.
Hear Shamika discuss her eczema clinical trial journey of discovery.
“If I could go through it again, I really would.”
About moderate to severe eczema (atopic dermatitis)
Moderate to severe eczema is a long-term condition. It happens when your immune system reacts too strongly to triggers around you, causing swelling under the skin. This can lead to itching, dryness, cracking, pain, or infection.
Symptoms may come and go over time. This type of eczema often affects large areas of the body (about 10% or more) and can make it hard to sleep, focus, or get through your day. Treatments can help, but many people still try different options to find relief.
